OptiNose Stock Forum

$OptiNose (OPTN.US)$
New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery
Optinose (NASDAQ:OPTN) announced the peer-reviewed publication of a paper in the International Forum of Allergy & Rhinology, highlighting the benefits of XHANCE in chronic rhinosinusitis (CRS) patients. The study, based on two 24-week randomized trials (ReOpen1 and ReOpen2), evaluated XHANCE versus EDS-placebo in CRS patients with and without prio...

$OptiNose (OPTN.US)$ Optinose Announced That Xhance (Fluticasone Propionate) Has Been Added To Express Scripts' National Formularies, Including The National Preferred, Flex, And Basic Formularies

$OptiNose (OPTN.US)$ 07:02 AM EDT, 05/14/2024 (MT Newswires) -- Earnings Flash (OPTN) OPTINOSE Posts Q1 Revenue $14.9M, vs. Street Est of $13.7M
OptiNose Q1 EPS USD -0.12 Vs. Ibes Estimate USD -0.11
Optinose Sees 2024 XHANCE Revenue in $85M to $95M Range >OPTN

$OptiNose (OPTN.US)$
NEWS
Optinose Announces $55 Million Registered Direct Offering

$Processa Pharmaceuticals (PCSA.US)$ $Barfresh Food (BRFH.US)$ $Intelligent Living Application (ILAG.US)$ $SuperCom (SPCB.US)$ $reAlpha Tech (AIRE.US)$ $OptiNose (OPTN.US)$
📊⚡️📊

$OptiNose (OPTN.US)$ SOPTN XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal
Polyps

$OptiNose (OPTN.US)$ Approved 🚀🚀🚀🚀

Last week’s PDUFAs:
$BeiGene (BGNE.US)$ : Approved 3/8 🎉
⇒ BRUKINSA + obinutuzumab
⇒ Follicular Lymphoma
⇒ sNDA
⇒ PDUFA date: Mar 2024
$Bristol-Myers Squibb (BMY.US)$ : Approved 3/8 🎉
⇒ Opdivo ®  + Cisplatin & Gemcitabine
⇒ Urothelial carcinoma
⇒ sBLA
⇒ PDUFA: 04/05/24
$Vanda Pharmaceuticals (VNDA.US)$ : CRL 3/4 🙁
⇒ HETLIOZ® 
⇒ insomnia
⇒ sNDA
⇒ PDUFA: 03/04/24
$Eyenovia (EYEN.US)$ : Approved 3/4 🎉
⇒ Clobetasol propionate ophthalmic susp. 0.05% (APP13007)
⇒ postop eye pa...